Active Ingredient History

  • Now
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel and Renvela.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1154 - $13.5483
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

gt16-026a | gt335-012 | renagel | renvela | sevelamer | sévélamer | sevelamer carbonate | sevelamer hcl | sevelamer hydrochloride | sevelamero | sevelamerum


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue